Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study

PR Newswire August 25, 2021

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021

PR Newswire August 5, 2021

Lipocine Announces Settlement With Clarus Therapeutics

PR Newswire July 14, 2021

Lipocine To Present At The Ladenburg Thalmann Healthcare Conference

PR Newswire July 6, 2021

Lipocine Announces Presentations at The International Liver Congress(TM) 2021 Digital Event

PR Newswire June 23, 2021

Lipocine To Present At The Raymond James Human Health Innovation Conference

PR Newswire June 16, 2021

FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

PR Newswire June 14, 2021

Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference

PR Newswire June 7, 2021

Summary Judgment Ruling in Patent Infringement Lawsuit

PR Newswire May 26, 2021

Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment

PR Newswire May 25, 2021

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021

PR Newswire May 6, 2021

Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference

PR Newswire March 11, 2021

Lipocine Announces Financial Results For The Year Ended December 31, 2020

PR Newswire March 11, 2021

Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis

PR Newswire March 4, 2021

Lipocine Announces Presentations on TLANDO(TM) at ENDO 2021 Conference

PR Newswire March 3, 2021

Lipocine to Present at Two Upcoming Investor Conferences

PR Newswire February 26, 2021

Lipocine Closes Underwritten Public Offering Of Common Stock

PR Newswire January 28, 2021

Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock

PR Newswire January 26, 2021

Lipocine Announces Launch Of Public Offering Of Common Stock

PR Newswire January 25, 2021

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

PR Newswire January 14, 2021